In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae

Yee Huang Ku, Yin Ching Chuang, Wen Liang Yu

Research output: Contribution to journalArticle

4 Citations (Scopus)


Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Results: The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively. Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

Original languageEnglish
Pages (from-to)332-336
Number of pages5
JournalJournal of Microbiology, Immunology and Infection
Issue number4
Publication statusPublished - Aug 2008



  • Beta-lactamase resistance
  • Beta-lactamases
  • Enterobacteriaceae
  • Microbial sensitivity tests
  • Minocycline

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Immunology and Allergy
  • Infectious Diseases
  • Microbiology (medical)

Cite this